Impact of PCSK9 Inhibitor on the Characteristics of Lipid-rich Coronary Plaques Assessed by Near-infrared Spectroscopy
Not Applicable
Recruiting
- Conditions
- Ischemic Heart Disease
- Registration Number
- JPRN-UMIN000040318
- Lead Sponsor
- Gifu Heart Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
(i) Patients with ST-elevated myocardial infarction (ii) Chronic renal disease manifested by estimated glomerular filtration rate of less than 40 ml/min/1.73 m2 (iii) Any clinically significant abnormality identified at screening visit, physical examination, laboratory tests, or comorbidities, which, in the judgment of the investigator, would preclude safe completion of the study (to continue LLTs or perform a follow-up NIRS-IVUS).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare administration of PCSK9i with statin-medication on coronary plaque components in patients with CAD using gray-scale- and NIRS- derived measurement
- Secondary Outcome Measures
Name Time Method To compare administration of PCSK9i with statin-medication on biomarker profiles